Register for the 2018 NIIMBL National Meeting

Latest News

NIIMBL to move into new Biopharmaceutical Innovation Building at the University of Delaware

October 23, 2017

Newark, DE, October 23, 2017 - The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced today it will move its headquarters into the University of Delaware’s new Biopharmaceutical Innovation Building, which is scheduled to open in 2020. NIIMBL participated in the groundbreaking ceremony for the building on Monday.

The building is owned and financed by the University of Delaware. NIIMBL will occupy nearly two stories of the six story, 200,000-square-foot building. The remaining space will house UD-led life science research and programs.

The NIIMBL space will include laboratories for project team collaboration, space to support worker training activities, and administrative offices.

NIIMBL Institute Director Kelvin Lee offered, “We are excited to be a part of this new building. The shared laboratories and facilities that will be created allow for tremendous synergy between NIIMBL’s activities and the life science research taking place at UD. We are grateful that the University will be making this space available to the NIIMBL community."

NIIMBL is a public-private consortium focused on biopharmaceutical manufacturing and workforce development. It brings together stakeholders from industry, academia, government agencies and non-profits to develop innovative manufacturing platforms and educate and train a biopharmaceutical manufacturing workforce, advancing U.S. competitiveness in this space.

NIIMBL is one of 14 Manufacturing USA institutes, each focused on different technologies and industry sectors. NIIMBL is sponsored by the National Institute of Standards and Technology (NIST) in the U.S. Department of Commerce. It is funded through a $70 million award over the next five-years from NIST and will leverage an expected $180 million from partners across industry, academia, non-profits, and state and local government.


The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private consortium with the goal of advancing innovation in biopharmaceutical manufacturing. The NIIMBL mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry. NIIMBL is a part of the Manufacturing USA network of institutes.

About Manufacturing USA

Manufacturing USA brings together industry, academia and government partners within a growing network of advanced manufacturing institutes to increase U.S. manufacturing competitiveness. Each institute is a public-private partnership that focuses on promoting robust and sustainable manufacturing research and development in a specific, promising advanced manufacturing technology area.

About Manufacturing USA

Dan Maiese
NIIMBL Communications Director

Related Coverage

Wilmington News Journal

Copyright 2017 NIIMBL. All rights reserved.

Department of Commerce National Institute of Standards and Technology Manufacturing USA USA Bio